Search | Clinical Trials Finder

Conditions: Overactive Bladder
Interventions: Solifenacin, Placebo; Drug · Other
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Urinary Incontinence, Parkinson's Disease
Interventions: Solifenacin Succinate (VESIcare), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, tamsulosin, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Over-Active Bladder
Interventions: Solifenacin succinate, Placebo; Drug
Lead sponsor: Advanced Research Network; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: fesoterodine fumarate, placebo, solifenacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more

Conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT); Drug · Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: Urinary Bladder, Overactive
Interventions: Placebo, Solifenacin Succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 59
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions: solifenacin succinate, placebo; Drug
Lead sponsor: Stamford Hospital; Other
Eligibility: 20 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Stamford, Connecticut

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin succinate suspension; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Urinary Bladder, Overactive
Interventions: VESIcare®, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Overactive Bladder
Interventions: PTNS plus solifenacin, Placebo; Other
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Overactive Bladder in Parkinson's Disease
Interventions: solifenacin succinate (VESIcare), placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia

Conditions: Post-micturition Incontinence, Incontinence
Interventions: solifenacin; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Over Active Bladder Patients Having Sling Surgery

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Anticholinergic vs. Botox Comparison Study

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

The Effect of Solifenacin on Post Void Dribbling in Women